Table 1. Characteristics of Adage patients at inclusion .
| Total | Rivaroxaban | Apixaban | p -Value | |
|---|---|---|---|---|
| n = 215 | n = 104 | n = 111 | ||
| Demographic characteristics | ||||
| Age (y) | 86.6 ± 4.3 | 86.4 ± 4.4 | 86.8 ± 4.3 | 0.491 |
| Females (%) | 71.2 | 68.3 | 73.9 | 0.371 |
| Body weight (kg) | 65.6 ± 14.7 | 64.9 ± 12.6 | 66.4 ± 16.5 | 0.543 |
| DOAC regimen | ||||
| Full dose (%) a | 20.5 | 17.3 | 23.4 | 0.312 |
| Reduced dose (%) b | 79.5 | 82.7 | 76.6 | 0.312 |
| Clinical characteristics | ||||
| Type of AF | ||||
| Persistent (%) | 9.1 | 8.7 | 9.4 | 0.978 |
| Paroxysmal (%) | 34.0 | 35.0 | 33.0 | 0.978 |
| Permanent (%) | 56.9 | 56.3 | 57.6 | 0.978 |
| Previous stroke or TIA (%) | 24.9 | 21.4 | 28.2 | 0.250 |
| Diabetes mellitus (%) †† | 19.0 | 10.9 | 26.6 | 0.005 |
| Hypertension (%) | 76.1 | 72.8 | 79.1 | 0.336 |
| Heart failure (%) | 49.8 | 46.6 | 52.7 | 0.412 |
| Dyslipidemia (%) | 26.4 | 24.3 | 28.4 | 0.535 |
| Clinical scores | ||||
| CHA 2 DS 2 VASc | 5.0 ± 1.4 | 4.9 ± 1.4 | 5.2 ± 1.4 | 0.122 |
| HEMORR2HAGES † | 2.3 ± 1.0 | 2.1 ± 1.0 | 2.5 ± 1.0 | 0.022 |
| CIRS-G † | 10.4 ± 4.5 | 9.3 ± 3.7 | 11.4 ± 4.8 | 0.007 |
| Laboratory data | ||||
| Creatinine clearance (mL/min) c | 49.1 ± 16.5 | 50.5 ± 17.1 | 47.9 ± 15.9 | 0.314 |
| Albumin (g/L) | 33.2 ± 5.2 | 33.4 ± 4.2 | 33.0 ± 5.9 | 0.756 |
| C-reactive protein (mg/L) | 28.8 ± 39.8 | 28.6 ± 41.9 | 28.9 ± 38.0 | 0.374 |
| Hemoglobin (g/dL) | 12.1 ± 1.7 | 12.2 ± 1.7 | 12.0 ± 1.8 | 0.400 |
| Fibrinogen (g/L) | 5.0 ± 1.5 | 4.9 ± 1.6 | 5.0 ± 1.4 | 0.309 |
| Therapeutic data | ||||
| Number of co-medications | 6.2 ± 2.7 | 5.9 ± 2.5 | 6.5 ± 2.9 | 0.256 |
| ≥1 P-gp substrate/inhibitor including amio. (%) | 48.3 | 44.6 | 51.8 | 0.292 |
| ≥1 CYP3A4/5 inhibitor including amio. (%) | 22.3 | 17.8 | 26.4 | 0.136 |
| Amiodarone (%) | 21.8 | 17.8 | 25.5 | 0.187 |
| Antiplatelet drugs (%) | 15.0 | 10.0 | 20.0 | 0.055 |
Abbreviations: AF, atrial fibrillation; Amio, amiodarone; TIA, transient ischemic attack.
Note: Data shown as percentage or mean ± standard deviation. Statistically significantly different values between the rivaroxaban and apixaban groups are indicated: † p < 0.05 or †† p < 0.01.
a
20 mg o.d. (rivaroxaban) or 5 mg b.i.d. (apixaban).
b
15 or 10 mg o.d. (rivaroxaban) or 2.5 mg b.i.d. (apixaban).
c
Estimated using the Cockcroft–Gault formula.